Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (321-330 of 466) with videos related to

Pageof 47
Sort By:
Blood|November 21, 2018
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximabAnton W Langerak, Matthias Ritgen, Valentin Goede, et al.
Bone Marrow Transplantation|November 13, 2021
Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational studyJohannes Schetelig, Jennifer Hoek, Stephan Stilgenbauer, et al.
The Lancet. Haematology|February 3, 2022
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Sandra Robrecht, et al.
Haematologica|November 10, 2018
The involvement of microRNA in the pathogenesis of Richter syndromeKatrien Van Roosbroeck, Recep Bayraktar, Steliana Calin, et al.
Bone Marrow Transplantation|August 18, 2020
Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational studyJohannes Schetelig, Jennifer Hoek, Stephan Stilgenbauer, et al.
Genome Medicine|March 20, 2020
Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLLJustyna A Wierzbinska, Reka Toth, Naveed Ishaque, et al.
The Lancet. Haematology|August 27, 2021
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trialAnna-Katharina Zoellner, Michael Unterhalt, Stephan Stilgenbauer, et al.
The Lancet. Oncology|August 18, 2018
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trialPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2021
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 StudyOthman Al-Sawaf, Can Zhang, Tong Lu, et al.
Nature Communications|October 20, 2022
Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escapeMaurizio Mangolini, Alba Maiques-Diaz, Stella Charalampopoulou, et al.
Pageof 47

Showing results (321-330 of 466) with videos related to

Sort By:
Pageof 47
Blood|November 21, 2018
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximabAnton W Langerak, Matthias Ritgen, Valentin Goede, et al.
Bone Marrow Transplantation|November 13, 2021
Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational studyJohannes Schetelig, Jennifer Hoek, Stephan Stilgenbauer, et al.
The Lancet. Haematology|February 3, 2022
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Sandra Robrecht, et al.
Haematologica|November 10, 2018
The involvement of microRNA in the pathogenesis of Richter syndromeKatrien Van Roosbroeck, Recep Bayraktar, Steliana Calin, et al.
Bone Marrow Transplantation|August 18, 2020
Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational studyJohannes Schetelig, Jennifer Hoek, Stephan Stilgenbauer, et al.
Genome Medicine|March 20, 2020
Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLLJustyna A Wierzbinska, Reka Toth, Naveed Ishaque, et al.
The Lancet. Haematology|August 27, 2021
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trialAnna-Katharina Zoellner, Michael Unterhalt, Stephan Stilgenbauer, et al.
The Lancet. Oncology|August 18, 2018
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trialPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2021
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 StudyOthman Al-Sawaf, Can Zhang, Tong Lu, et al.
Nature Communications|October 20, 2022
Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escapeMaurizio Mangolini, Alba Maiques-Diaz, Stella Charalampopoulou, et al.
Pageof 47